Literature DB >> 27000997

The elusive minimum threshold concentration of levonorgestrel for contraceptive efficacy.

Ganesh Cherala1, Alison Edelman2, Laneta Dorflinger3, Frank Z Stanczyk4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27000997     DOI： 10.1016/j.contraception.2016.03.010

Source DB:  PubMed          Journal:  Contraception        ISSN： 0010-7824            Impact factor:   3.375


× No keyword cloud information.
  14 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

Review 2.  Biomaterials and Contraception: Promises and Pitfalls.

Authors:  Isabella Claure; Deborah Anderson; Catherine M Klapperich; Wendy Kuohung; Joyce Y Wong
Journal:  Ann Biomed Eng       Date:  2019-11-07       Impact factor: 3.934

3.  Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.

Authors:  Lauren R Cirrincione; Sujan Dilly Penchala; Kimberly K Scarsi; Anthony T Podany; Lee C Winchester; David J Back; Saye H Khoo; Courtney V Fletcher; Marco Siccardi; Laura J Else
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-03-12       Impact factor: 3.205

4.  Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.

Authors:  Andrea R Thurman; Vivian Brache; Leila Cochon; Louise A Ouattara; Neelima Chandra; Terry Jacot; Nazita Yousefieh; Meredith R Clark; Melissa Peet; Homaira Hanif; Jill L Schwartz; Susan Ju; Mark A Marzinke; David W Erikson; Urvi Parikh; Betsy C Herold; Raina N Fichorova; Elizabeth Tolley; Gustavo F Doncel
Journal:  PLoS One       Date:  2022-10-10       Impact factor: 3.752

5.  Double Dosing Levonorgestrel-Based Emergency Contraception for Individuals With Obesity: A Randomized Controlled Trial.

Authors:  Alison B Edelman; Jon D Hennebold; Kise Bond; Jeong Y Lim; Ganesh Cherala; David F Archer; Jeffrey T Jensen
Journal:  Obstet Gynecol       Date:  2022-06-07       Impact factor: 7.623

Review 6.  Clarification of contraceptive drug pharmacokinetics in obesity.

Authors:  William J Jusko
Journal:  Contraception       Date:  2016-08-16       Impact factor: 3.375

Review 7.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

Review 8.  Drug interactions between hormonal contraceptives and antiretrovirals.

Authors:  Kavita Nanda; Gretchen S Stuart; Jennifer Robinson; Andrew L Gray; Naomi K Tepper; Mary E Gaffield
Journal:  AIDS       Date:  2017-04-24       Impact factor: 4.177

9.  Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Authors:  Andrea Ries Thurman; Jill L Schwartz; Vivian Brache; Meredith R Clark; Timothy McCormick; Neelima Chandra; Mark A Marzinke; Frank Z Stanczyk; Charlene S Dezzutti; Sharon L Hillier; Betsy C Herold; Raina Fichorova; Susana N Asin; Christiane Rollenhagen; Debra Weiner; Patrick Kiser; Gustavo F Doncel
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

10.  Rational Design of a Multipurpose Bioadhesive Vaginal Film for Co-Delivery of Dapivirine and Levonorgestrel.

Authors:  Jing Li; Galit Regev; Sravan Kumar Patel; Dorothy Patton; Yvonne Sweeney; Philip Graebing; Sheila Grab; Lin Wang; Vinayak Sant; Lisa C Rohan
Journal:  Pharmaceutics       Date:  2019-12-18       Impact factor: 6.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.